Intuitive Surgical, Inc. — FY 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. This is an annual report, not a standalone fourth-quarter filing; selected Q4 figures are included below. The company designs, manufactures, and sells da Vinci surgical systems, instruments and accessories, and related services. It reports one operating segment.
Business context and operating performance
Approximately 652,000 procedures were performed using da Vinci systems in 2015, up about 14% from 570,000 in 2014. The installed base grew to 3,597 systems from 3,266. U.S. procedures rose about 11% and procedures outside the U.S. about 26%; growth was led by U.S. general surgery and international adoption, particularly in Asia.
| Metric | FY 2015 | FY 2014 | Change |
|---|---|---|---|
| Revenue | $2.384 billion | $2.132 billion | +12% |
| Gross profit / gross margin | $1.578 billion / 66% | $1.414 billion / 66% | +12% gross profit |
| Operating income / margin | $740.0 million / 31% | $544.8 million / 26% | +36% |
| Net income | $588.8 million | $418.8 million | +41% |
| Diluted EPS | $15.54 | $11.11 | +40% |
| Operating cash flow | $771.9 million | $665.1 million | +16% |
| Cash, cash equivalents, and investments | $3.348 billion | $2.497 billion | +$850.8 million |
Product revenue was $1.920 billion, including $1.198 billion from instruments and accessories and $721.9 million from systems. Service revenue was $464.8 million. Recurring revenue reached $1.663 billion, or 70% of total revenue, unchanged as a share of sales from 2014. System shipments increased to 492 from 431. Product gross margin was 66.3%, slightly below 66.5% in 2014; service gross margin was 65.7%, versus 65.5%.
At December 31, 2015, current assets were $2.196 billion and current liabilities $491.9 million. Total liabilities were $587.8 million and stockholders’ equity was $4.320 billion. The balance sheet presents no separate borrowings or debt line; confirm debt and other financing commitments in the full statements and notes.
Q4 2015: Revenue was $676.5 million, gross profit $458.8 million, net income $190.0 million, and diluted EPS $4.99. The filing does not present a standalone Q4 cash-flow statement.
Material changes and notable items
- Revenue rebounded from a 6% decline in 2014, when system revenue fell 24%, to 12% growth in 2015. FY 2015 system revenue rose 14%; recurring revenue rose 11%.
- Operating income improved partly because SG&A fell to $640.5 million from $691.0 million. Product-liability litigation charges were $13.2 million in 2015 versus $82.4 million in 2014.
- Net income includes a $29.3 million discrete tax benefit in Q3, associated with a U.S. Tax Court opinion, and other tax benefits. The effective tax rate was 22.4%, compared with 23.7% in 2014.
- R&D expense increased 11% to $197.4 million; management said it expects substantial continued investment and anticipates R&D expense to increase.
- The company repurchased $183.7 million of stock in 2015, compared with $1.0 billion in 2014. It had $816.3 million remaining under its repurchase authorization at year-end.
Outlook, risks, and contingencies
Management said cash, investments, and expected operating cash flows should be sufficient to fund requirements beyond one year and for the foreseeable future. It expects international procedures and revenue to grow faster than U.S. activity, while noting that future system demand depends on procedure growth, system utilization, product adoption, regulatory clearances, reimbursement, and government tender timing. No numeric revenue or earnings guidance is provided in the supplied filing text.
- Legal/product liability: The company reported approximately 92 individual product-liability lawsuits and a multi-plaintiff suit involving 55 patients. It recorded $13.8 million in FY 2015 charges for certain claims and accrued $24.4 million for tolled claims at year-end. It said additional losses were reasonably possible but could not estimate an excess loss range. The company self-insures product-liability risk.
- Product actions: A voluntary recall followed a 2014 suspension of the EndoWrist Stapler 45 for the Si system; replacement instruments began shipping in 2015. A 2015 safety notice concerned certain equipment drapes. These actions could affect costs, reputation, utilization, and sales.
- Regulatory and reimbursement exposure: Japanese reimbursement was broadly available only for prostatectomy, while additional procedure reimbursement remained uncertain. China system placements depended on import authorization and central purchasing tenders; the most recent authorization expired at year-end 2015.
- Competition and adoption: The company faces alternatives including open surgery, conventional minimally invasive surgery, and emerging robotic systems. Adoption depends on clinical and economic value, training, reimbursement, and hospital capital spending.
- Margins, currency, and supply: Newer products can carry lower margins; a stronger U.S. dollar reduced revenue and can affect affordability abroad. Sole- or single-source suppliers and limited finished-goods inventories create supply continuity risks.
- Tax and policy: The 2.3% U.S. medical-device excise tax cost $17.0 million in 2015. A two-year moratorium covers 2016–2017; absent further legislation, the tax is scheduled to resume in 2018.
Key facts for investors to verify
- Whether procedure growth, particularly in U.S. general surgery and Asian markets, translates into sustained instrument, service, and system revenue growth.
- The durability of the 2015 earnings improvement, including the one-time tax benefit and lower litigation charges.
- Updates on product-liability claims, insurance disputes, accrual adequacy, and any potential losses beyond recorded amounts.
- Progress on China purchasing authorizations and Japanese reimbursement for procedures beyond prostatectomy.
- System utilization, product mix, and margin trends as Xi systems and newer instruments scale.
- Cash-flow conversion, investment portfolio risks, share-based compensation, and the effect of future repurchases on share count.